Using multiple measures of glycemia to support individualized diabetes management: Recommendations for clinicians, patients, and payers

Diabetes Technology and Therapeutics

Volumn 14, Issue 11, 2012, Pages 973-983

  Hirsch, Irl B ^a   Amiel, Stephanie A ^b   Blumer, Ian R ^c   Bode, Bruce W ^d,e   Edelman, Steven V ^f   Seley, Jane J ^g   Verderese, Carol A ^h   Kilpatrick, Eric S ⁱ  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c Charles H Best Diabetes Centre   (Canada)

^d ATLANTA DIABETES ASSOCIATES   (United States)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g NewYork Presbyterian/Weill Cornell   (United States)

^h Diabetes Education Group   (United States)

ⁱ UNIVERSITY OF HULL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FRUCTOSAMINE; GLUCOSE; HEMOGLOBIN A1C; INSULIN;

ACCREDITATION; BLOOD GLUCOSE MONITORING; DIABETES MELLITUS; DIET RESTRICTION; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEALTH CARE DISPARITY; HEALTH CARE SYSTEM; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MEDICAL EDUCATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NURSING EDUCATION; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; SELF CARE; SELF MONITORING;

BIOLOGICAL MARKERS; BLOOD GLUCOSE; BLOOD GLUCOSE SELF-MONITORING; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; EDUCATION, MEDICAL, CONTINUING; EUROPE; FEMALE; FRUCTOSAMINE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; INDIVIDUALIZED MEDICINE; MALE; NORTH AMERICA; NURSES; PHYSICIANS; RISK FACTORS;

EID: 84868036087     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2012.0132     Document Type: Review

References (60)

1. International Diabetes Federation: IDF Atlas, 5th ed. Brussels: International Diabetes Federation, 2011. www/idf.org/diabetesatlas (accessed July 2012).
2. Dall TM, Zhang Y, Chen YJ, Quick WW, Yang WG, Fogli J: The economic burden of diabetes. Health Aff (Millwood) 2010;29:297-303.
3. Hoerger TJ, Segel JE, Gregg EW, Saaddine JB: Is glycemic control improving in U.S. adults? Diabetes Care 2008;31: 81-86.
4. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329:977-986.
5. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352:837-853.
6. American Diabetes Association: Standards of medical care in diabetes - 2012. Diabetes Care 2012;35(Suppl 1):S11-S63.
7. Handelsman Y, Mechanick JI, Blonde L, Grunberger G, Bloomgarden ZT, Bray GA, Dagogo-Jack S, Davidson JA, Einhorn D, Ganda O, Garber AJ, Hirsch IB, Horton ES, Ismail- Beigi F, Jellinger PS, Jones KL, Jovanovic L, Lebovitz H, Levy P, Moghissi ES, Orzeck EA, Vinik AI, Wyne KL; AACE Task Force for Developing Diabetes Comprehensive Care Plan: American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan. Endocr Pract 2011;17:1-53.
8. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee: Canadian Diabetes Association. 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2008;32(Suppl): S1-S201.
9. National Collaborating Centre for Chronic Conditions: Type 2 Diabetes: National Clinical Guideline for Management in Primary and Secondary Care (Update). London: Royal College of Physicians, 2008.
10. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B; American Diabetes Association; European Association for Study of Diabetes: Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203.
11. Qaseem A, Humphrey LL, Sweet DE, Starkey M, Shekelle P; Clinical Guidelines Committee of the American College of Physicians: Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2012;156:218-231.
12. International Diabetes Federation: Guidelines for management of postmeal glucose in diabetes 2011. www.idf.org/2011-guideline-management-postmeal- glucose-diabetes (accessed July 2012).
13. Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EA, Howard BV, Kirkman MS, Kosiborod M, Reaven P, Sherwin RS; American Diabetes Association; American College of Cardiology Foundation; American Heart Association: Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care 2009;32:187-192.
14. Ismail-Beigi F, Moghissi E, Tiktin M, Hirsch IB, Inzucchi SE, Genuth S: Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials. Ann Intern Med 2011;154:554-559.
15. Desai NR, Shrank WH, Fischer MA, Avorn J, Liberman JN, Schneeweiss S, Pakes J, Brennan TA, Choudhry NK: Patterns of medication initiation in newly diagnosed diabetes mellitus: quality and cost implications. Am J Med 2012;125: 302el-302e7.
16. Grant RW, Wexler DJ, Watson AJ, Lester WT, Cagliero E, Campbell EG, Nathan DM: How doctors choose medications to treat type 2 diabetes. Diabetes Care 2007;30:1448-1453.
17. Cohen RM: A1C: Does one size fit all? Diabetes Care 2007; 30:2756-2758. (Pubitemid 47547834)
18. Zhang L, Krzentowski G, Albert A, Lefebvre PJ: Risk of developing retinopathy in Diabetes Control and Complications Trial Type 1 diabetic patients with good or poor metabolic control. Diabetes Care 2001;24:1275-1279. (Pubitemid 33716411)
19. Hirsch IB, Brownlee M: Beyond hemoglobin A1c - need for additional markers of risk for diabetic microvascular complications. JAMA 2010;303:2291-2292.
20. Lachin JM, Genuth S, Nathan DM, Zinman B, Rutledge BN, DCCT/EDIC Research Group: Effect of glycemic exposure on the risk of microvascular complications in the diabetes control and complications trial - revisited. Diabetes 2008;57: 995-1001.
21. Chukwu J, Weiland K, Dungan K, Hirsch IB, Trence DL: Frequency of inability to use A1C as marker of glycemic control in two academic diabetes clinics [poster 878-P]. Diabetes 2012;61(Suppl 1):A223.
22. Herman WH: Do race and ethnicity impact hemoglobin A1c independent of glycemia? J Diabetes Sci Technol 2009;3: 656-660.
23. Rubinow KB, Hirsch IB: Reexamining metrics for glucose control. JAMA 2011;305:1132-1133.
24. Saudek CD, Derr RL, Kalyani RR: Assessing glycemia in diabetes using self-monitoring of blood glucose and hemoglobin A1C. JAMA 2006;295:1688-1697.
25. Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ; Alc-Derived Average Glucose Study Group: Translating the A1C assay into estimated average glucose values. Diabetes Care 2008;31:1473-1478.
26. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group,Wilson DM, Xing D, Beck RW, Block J, Bode B, Fox LA, Hirsch I, Kollman C, Laffel L, Ruedy KJ, Steffes M, Tamborlane WV: Hemoglobin A1c and mean glucose in patients with type 1 diabetes: analysis of data from the Juvenile Diabetes Research Foundation continuous glucose monitoring randomized trial. Diabetes Care 2011;34: 540-544.
27. Kilpatrick ES, Rigby AS, Atkin SL: Variability in the relationship between mean plasma glucose and HbA1c: implications for the assessment of glycemic control. Clin Chem 2007;53:897-901. (Pubitemid 46744246)
28. Herman WH, Cohen RM: Racial and ethnic differences in the relationship between HbA1c and blood glucose: implications for diagnosis of diabetes. J Clin Endocrinol Metab 2012;97:1067-1072.
29. Bartol T: Comparison of blood glucose, HbA1c, and fructosamine. www.healthyinfo.com/clinical/endo/dm/hga1c .test.shtml (accessed May 19, 2012).
30. Nathan DM, Singer DE, Hurxthal K, Goodson JD: The clinical information value of the glycosylated hemoglobin assay. N Engl J Med 1984;310:341-346. (Pubitemid 14179538)
31. Lachin JM, Genuth S, Nathan DM, Rutledge BN: The hemoglobin glycation index is not an independent predictor of the risk of microvascular complications in the Diabetes Control and Complications Trial. Diabetes 2007;56: 1913-1921. (Pubitemid 47025457)
32. Kilpatrick ES, Rigby AS, Goode K, Atkin SL: Relating mean blood glucose and glucose variability to the risk of multiple episodes of hypoglycaemia in type 1 diabetes. Diabetologia 2007;50:2553-2561. (Pubitemid 350060641)
33. Monnier L, Wojtusciszyn A, Colette C, Owens D: The contribution of glucose variability to asymptomatic hypoglycemia in persons with type 2 diabetes. Diabetes Technol Ther 2011;13:813-818.
34. Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, Colette C: Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 2006;295:1681-1687.
35. Kilpatrick ES, Rigby AS, Atkin SL: A1C variability and the risk of microvascular complications in type 1 diabetes: data from the Diabetes Control and Complications Trial. Diabetes Care 2008;31:2198-2202.
36. Riddle MC, Abrosius WT, Brillon DJ, Buse JB, Byington RP, Cohen RM, Goff DC Jr, Malozowski S, Margolis KL, Probstfield JL, Schnall A, Seaquist ER; Action to Control Cardiovascular Risk in Diabetes Investigators: Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care 2010;33:983-990.
37. Riddle M, Ahmann A, Basu A, Aroda V, Ratner R:Metformin + exenatide + basal insulin vs metformin + placebo + basal insulin: reaching A1c < 6.5% without weight-gain or serious hypoglycemia [poster 18-LB]. Diabetes 2010;59(Suppl 1A):LB6.
38. Monnier L, Colette C, Dunseath GJ, Owens DR: The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes. Diabetes Care 2007;30:263-269. (Pubitemid 46198328)
39. Shiraiwa T, Kaneto H, Miyatsuka T, Kato K, Yamamoto K, Kawashima A, Kanda T, Suzuki M, Imano E, Matsuhisa M, Hori M, Yamasaki Y: Postprandial hyperglycemia is a better predictor of the progression of diabetic retinopathy than HbA1c in Japanese type 2 diabetic patients. Diabetes Care 2005;28:2806-2807. (Pubitemid 43951181)
40. Levitan EB, Song Y, Ford ES, Liu S: Is nondiabetic hyperglycemia a risk factor for cardiovascular disease? A metaanalysis of prospective studies. Arch Intern Med 2004;164: 2147-2155. (Pubitemid 39410805)
41. Gerich JE: Clinical significance, pathogenesis, and management of postprandial hyperglycemia. Arch Intern Med 2003; 163:1306-1316. (Pubitemid 36676195)
42. Cavalot F, Petrelli A, Traversa M, Bonomo K, Fiora E, Conti M, Anfossi G, Costa G, Trovati M: Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: lesson from the San Luigi Gonzaga Diabetes Study. J Clin Endocrinol Metab 2006;91:813-819. (Pubitemid 43357744)
43. Rendell MS, Jovanovic L: Targeting postprandial hyperglycemia. Metabolism 2006;55:1263-1281. (Pubitemid 44215947)
44. Dungan KM: 1,5-Anhydroglucitol (GlycoMark) as a marker of short-term glycemic control and glycemic excursions. Expert Rev Mol Diagn 2008;8:9-19.
45. Hirsch IB, Bode BW, Childs BP, Close KL, Fisher WA, Gavin JR, Ginsberg BH, Raine CH, Verderese CA: Self-monitoring of blood glucose (SMBG) in insulin- and non-insulin-using adults with diabetes: consensus recommendations for improving SMBG accuracy, utilization, and research. Diabetes Technol Ther 2008;10:419-439.
46. Weber C, Schnell O: The assessment of glycemic variability and its impact on diabetes-related complications: an overview. Diabetes Technol Ther 2009;11:623-633.
47. Hirsch IB: Blood glucose monitoring technology: translating data into practice. Endocr Pract 2004;10:67-76.
48. Reach G: Can technology improve adherence to long-term therapies? J Diabetes Sci Technol 2009;3:492-499.
49. Simmons D, Lillis S, Swan J, Haar J: Discordance in perceptions of barriers to diabetes care between patients and primary care and secondary care. Diabetes Care 2007;30:490-495. (Pubitemid 46354323)
50. Ratanawongsa N, Crosson JC, Schillinger D, Karter AJ, Saha CK, Marrero DG: Getting under the skin of clinical inertia in insulin initiation: the Translating Research Into Action for Diabetes (TRIAD) insulin starts project. Diabetes Educ 2012; 38:94-100.
51. Fisher L, Polonsky WH, Parkin CG, Jelsovsky Z, Petersen B, Wagner RS: The impact of structured blood glucose testing on attitudes toward self-management among poorly controlled insulin-naïve patients with type 2 diabetes. Diabetes Res Clin Pract 2012;96:149-155.
52. Choe C, Edelman SV: The role of self-monitoring of blood glucose during the treatment of type 2 diabetes with medications targeting postprandial hyperglycemia. South Med J 2007;100:1123-1131. (Pubitemid 350071179)
53. Poolsup N, Suksomboon N, Rattanasookchit S: Meta-analysis of the benefits of self-monitoring of blood glucose on glycemic control in type 2 diabetes patients: an update. Diabetes Technol Ther 2009;11:775-784.
54. McGeoch G, Derry S, Moore RA: Self-monitoring of blood glucose in type-2 diabetes: what is the evidence? Diabetes Metab Res Rev 2007;23:423-440. (Pubitemid 47520901)
55. Davies M, Storms F, Shutler S, Bianchi-Biscay M, Gomis R; AT.LANTUS Study Group: Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine. Diabetes Care 2005;28:1282-1288. (Pubitemid 40756686)
56. Budnitz DS, Lovegrove MC, Shehab N, Richards CL: Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med 2011;365:2002-2012.
57. Dall TM, Mann SE, Zhang Y, Quick WW, Seifert RF, Martin J, Huang EA, Zhang S: Distinguishing the economic costs associated with type 1 and type 2 diabetes. Popul Health Manag 2009;12:103-110.
58. Peyrot M, Rubin RR, Funnell MM, Siminerio LM: Access to diabetes self-management education: results of national surveys of patients, educators, and physicians. Diabetes Educ 2009;35:246-248, 252-256, 258-263.
59. Powell MP, Glover SH, Probst JC, Laditka SB: Barriers associated with the delivery of Medicare-reimbursed diabetes self-management education. Diabetes Educ 2005;31:890-899. (Pubitemid 41771882)
60. Duncan I, Ahmed T, Li QE, Stetson B, Ruggiero L, Burton K, Rosenthal D, Fitzner K: Assessing the value of the diabetes educator. Diabetes Educ 2011;37:638-657.